Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 205.55

-1.3%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (29386)	11/15/1999 11:13:00 AM
From: bob zagorin	Read Replies (2) of 32384

Henry, I know LGND is strong on SERM research. Any comment on this from Jim McCamant's newsletter on AXPH SERM deal with Signal. "...The company also announced that they have established a partnership with the San Diego-based, private biotech company Signal Pharmaceuticals. Under the terms of the deal, AXPH will gain exclusive worldwide rights to Signal's selective estrogen receptor-beta modulators to treat cancer. These compounds act on the beta subtype of the estrogen receptor, which is located on various types of cancer cells. In exchange for these rights, AXPH will pay an undisclosed licensing fee and make research payments to Signal, and will also make milestone and potential royalty payments. There is also a provision included in the collaboration that gives Signal the option to share equally in U.S. profits. If they take advantage of this, then they will also share equally in the R & D costs. Signal will retain all rights to these compounds outside the cancer area. This is AXPH's first of what will likely be many in-licensing deals for their cancer program. AXPH is a buy under $8...."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next